Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.

Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK.

Eur J Cancer. 2019 Dec 27;126:1-10. doi: 10.1016/j.ejca.2019.10.032. [Epub ahead of print]

2.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]

PMID:
31331862
3.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L.

J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.

PMID:
31194611
4.

Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.

Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B.

Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703. doi: 10.1016/j.clgc.2019.03.017. Epub 2019 Apr 1.

5.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

6.

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.

Proskorovsky I, Benedict A, Negrier S, Bargo D, Sandin R, Ramaswamy K, Desai J, Cappelleri JC, Larkin J.

BMC Cancer. 2018 Dec 19;18(1):1271. doi: 10.1186/s12885-018-5157-0.

7.

Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.

Négrier S, Moriceau G, Attignon V, Haddad V, Pissaloux D, Guerin N, Carrie C.

J Med Case Rep. 2018 Nov 25;12(1):351. doi: 10.1186/s13256-018-1875-9.

8.

20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.

Bellocq D, Roy P, Kodjikian L, Mathis T, Nguyen AM, Herault J, Rivoire M, Négrier S, Thariat J, Grange JD.

Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000519. [Epub ahead of print]

PMID:
30320630
9.

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.

Guillot A, Joly C, Barthélémy P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K.

Clin Genitourin Cancer. 2019 Feb;17(1):e38-e43. doi: 10.1016/j.clgc.2018.08.006. Epub 2018 Sep 6.

PMID:
30279115
10.

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.

Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G.

Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018.

11.

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pages G, Vilgrain I.

Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22.

12.

Individualized dosing with axitinib: rationale and practical guidance.

Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, Rini B, Négrier S.

Future Oncol. 2018 Apr;14(9):861-875. doi: 10.2217/fon-2017-0455. Epub 2017 Dec 21. Review.

13.

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Figlin RA, Leibovich BC, Stewart GD, Negrier S.

Ann Oncol. 2018 Feb 1;29(2):324-331. doi: 10.1093/annonc/mdx743. Review.

PMID:
29186296
14.

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

Stewart GD, Leibovich BC, Negrier S, Figlin RA.

J Clin Oncol. 2017 Dec 10;35(35):3895-3897. doi: 10.1200/JCO.2017.75.4242. Epub 2017 Oct 25. No abstract available.

PMID:
29068785
15.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G.

Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.

16.

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.

Négrier S, Pérol D, Bahleda R, Hollebecque A, Chatelut E, Boyle H, Cassier P, Metzger S, Blanc E, Soria JC, Escudier B.

BMC Cancer. 2017 Aug 15;17(1):547. doi: 10.1186/s12885-017-3527-7.

17.

How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.

Bracarda S, Negrier S, Casper J, Porta C, Schmidinger M, Larkin J, Gross Goupil M, Escudier B.

Expert Rev Anticancer Ther. 2017 Mar;17(3):227-233. doi: 10.1080/14737140.2017.1276830. Epub 2017 Jan 3. Review.

PMID:
28044472
18.

Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.

Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, Nathan P, Negrier S, Weiss C, Porta C, Grünwald V, Albiges L.

Eur J Cancer. 2016 Dec;69:226-235. doi: 10.1016/j.ejca.2016.08.004. Epub 2016 Sep 24.

PMID:
27680407
19.

[Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer].

Soria JC, Bastian G, Bolotine L, Calais G, Céraline J, de Cremoux P, Espié M, Karayan-Tapon L, Laprie A, Mazeron JJ, Négrier S, Roché H.

Bull Cancer. 2016 Sep;103(9):719-29. doi: 10.1016/j.bulcan.2016.07.004. Epub 2016 Aug 23. French. No abstract available.

PMID:
27561824
20.

Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report.

Langrand-Escure J, Vallard A, Rivoirard R, Méry B, Guy JB, Espenel S, Trone JC, Ben Mrad M, Diao P, Rancoule C, Suchaud JP, Fournel P, Guillot A, Chargari C, Escudier B, Négrier S, Magné N.

Anticancer Drugs. 2016 Jun;27(5):427-32. doi: 10.1097/CAD.0000000000000349.

PMID:
27045782
21.

First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.

Le Saux O, Freyer G, Négrier S.

Clin Drug Investig. 2016 May;36(5):389-99. doi: 10.1007/s40261-016-0384-0. Review.

PMID:
26945986
22.

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Imbs DC, Paludetto MN, Négrier S, Powell H, Lafont T, White-Koning M, Chatelut E, Thomas F.

Invest New Drugs. 2016 Feb;34(1):41-8. doi: 10.1007/s10637-015-0304-9. Epub 2015 Nov 16.

PMID:
26572909
23.

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.

Jobard E, Blanc E, Négrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, Trédan O.

Br J Cancer. 2015 Oct 20;113(8):1148-57. doi: 10.1038/bjc.2015.322. Epub 2015 Sep 15.

24.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group.

Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Review.

PMID:
26371288
25.

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.

Tang Y, Bycott P, Akerborg O, Jönsson L, Negrier S, Chen C.

Cancer Manag Res. 2014 Sep 22;6:365-71. doi: 10.2147/CMAR.S67249. eCollection 2014.

26.

Small metastasizing choroidal melanomas.

Malclès A, Kivelä T, Svetlosakova Z, Jean-Louis B, Nguyen AM, Sallit R, Négrier S, Pommier P, Rivoire M, Chauvel P, Mammar H, Devouassoux-Shisheboran M, Kodjikian L, Denis P, Grange JD.

Acta Ophthalmol. 2015 Mar;93(2):e160-6. doi: 10.1111/aos.12523. Epub 2014 Aug 13.

27.

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ.

Eur J Cancer. 2014 Jul;50(10):1766-1771. doi: 10.1016/j.ejca.2014.03.012. Epub 2014 Apr 23.

28.

Pharmacokinetics of pazopanib administered in combination with bevacizumab.

Imbs DC, Négrier S, Cassier P, Hollebecque A, Varga A, Blanc E, Lafont T, Escudier B, Soria JC, Pérol D, Chatelut E.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1189-96. doi: 10.1007/s00280-014-2455-3. Epub 2014 Apr 6.

PMID:
24705975
29.

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D.

J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31.

PMID:
24687826
30.

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ.

Cancer. 2014 Jun 15;120(12):1871-80. doi: 10.1002/cncr.28660. Epub 2014 Mar 13.

31.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.

Ann Oncol. 2014 Mar;25(3):742-6. doi: 10.1093/annonc/mdt585. Epub 2014 Feb 7.

32.

The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.

Grépin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H, Pagès G.

Cancer Res. 2014 Feb 1;74(3):873-83. doi: 10.1158/0008-5472.CAN-13-1267. Epub 2013 Dec 12.

33.

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.

Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Négrier S; French Group on Renal Cancer.

Clin Genitourin Cancer. 2014 Feb;12(1):50-4. doi: 10.1016/j.clgc.2013.09.008. Epub 2013 Sep 28.

PMID:
24268852
34.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

35.

Sorafenib and sunitinib for elderly patients with renal cell carcinoma.

Derbel Miled O, Dionne C, Terret C, Segura-Ferlay C, Flechon A, Neidhart EM, Negrier S, Droz JP.

J Geriatr Oncol. 2013 Jul;4(3):255-61. doi: 10.1016/j.jgo.2013.04.004. Epub 2013 May 9.

PMID:
24070463
36.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI.

Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Erratum in: Lancet Oncol. 2013 Jun;14(7):e254.

PMID:
23598172
37.

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.

Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S.

Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548.

38.

Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.

Larkin J, Fishman M, Wood L, Negrier S, Olivier K, Pyle L, Gorbunova V, Jonasch E, Andrews L, Staehler M.

Am J Clin Oncol. 2014 Aug;37(4):397-403. doi: 10.1097/COC.0b013e31827b45f9.

PMID:
23357974
39.

Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.

Gigante M, Li G, Ferlay C, Perol D, Blanc E, Paul S, Zhao A, Tostain J, Escudier B, Negrier S, Genin C.

Anticancer Res. 2012 Dec;32(12):5447-51.

PMID:
23225450
40.

Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.

Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ.

J Urol. 2012 Dec;188(6):2095-100. doi: 10.1016/j.juro.2012.08.026. Epub 2012 Oct 18.

PMID:
23083849
41.

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.

Br J Cancer. 2012 May 8;106(10):1587-90. doi: 10.1038/bjc.2012.149.

42.

Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.

Négrier S.

Oncology. 2012;82(4):189-96. doi: 10.1159/000336888. Epub 2012 Mar 21. Review.

PMID:
22440948
43.

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.

Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K.

Eur J Cancer. 2012 Mar;48(5):721-7. doi: 10.1016/j.ejca.2012.01.011. Epub 2012 Feb 6. Review.

PMID:
22317952
44.

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B.

J Clin Oncol. 2012 Feb 10;30(5):482-7. doi: 10.1200/JCO.2011.37.2516. Epub 2012 Jan 9.

PMID:
22231040
45.

Addition of bevacizumab to temsirolimus in kidney cancer patients.

Boyle H, Négrier S.

Case Rep Oncol. 2011 Sep;4(3):531-3. doi: 10.1159/000334581. Epub 2011 Nov 11.

46.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ.

Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Erratum in: Lancet. 2012 Nov 24;380(9856):1818.

PMID:
22056247
47.

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.

Grepin R, Guyot M, Jacquin M, Durivault J, Chamorey E, Sudaka A, Serdjebi C, Lacarelle B, Scoazec JY, Negrier S, Simonnet H, Pages G.

Oncogene. 2012 Mar 29;31(13):1683-94. doi: 10.1038/onc.2011.360. Epub 2011 Sep 12.

PMID:
21909141
48.

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.

Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Négrier S, Escudier B, Eisen T, Dutcher J, Atkins M, Heng DY, Choueiri TK, Motzer R, Bukowski R; International Kidney Cancer Working Group.

Clin Cancer Res. 2011 Aug 15;17(16):5443-50. doi: 10.1158/1078-0432.CCR-11-0553. Epub 2011 Aug 9.

49.

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME.

Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12.

50.

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B.

Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12.

PMID:
21664867

Supplemental Content

Loading ...
Support Center